U.S. markets closed
  • S&P Futures

    4,076.75
    -13.25 (-0.32%)
     
  • Dow Futures

    34,073.00
    -83.00 (-0.24%)
     
  • Nasdaq Futures

    12,089.75
    -62.25 (-0.51%)
     
  • Russell 2000 Futures

    1,934.30
    -5.10 (-0.26%)
     
  • Crude Oil

    79.06
    +0.19 (+0.24%)
     
  • Gold

    1,924.70
    -4.80 (-0.25%)
     
  • Silver

    23.73
    -0.11 (-0.47%)
     
  • EUR/USD

    1.0855
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    3.5290
    -0.0220 (-0.62%)
     
  • Vix

    19.40
    -0.54 (-2.71%)
     
  • GBP/USD

    1.2305
    -0.0012 (-0.10%)
     
  • USD/JPY

    130.0770
    +0.0090 (+0.01%)
     
  • BTC-USD

    23,112.20
    +204.78 (+0.89%)
     
  • CMC Crypto 200

    524.33
    +5.54 (+1.07%)
     
  • FTSE 100

    7,771.70
    -13.17 (-0.17%)
     
  • Nikkei 225

    27,375.95
    +48.84 (+0.18%)
     

Biotricity Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

Biotricity, Inc.

Biocare Cardiac is the first-of-its-kind comprehensive cardiac disease management solution combining diagnostics, RPM, disease and lifestyle management, and telemedicine for cardiologists and patients.

REDWOOD CITY, CA / ACCESSWIRE / October 26, 2022 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac. The national roll-out follows two successful pilot programs in Oklahoma City with CardioVascular Health Clinic, a medical facility providing high-quality cardiovascular care to more than 40,000 patients, and a four-month pilot with Lexington Heart Specialists in Kentucky, a medical practice providing high-quality cardiovascular care to more than 20,000 patients.

Designed to expand Biotricity's existing remote monitoring tools used today by more than 2,000 cardiologists nationwide, the easy-to-use solution puts actionable data at the physicians' fingertips to assist them in making treatment decisions quickly.

Biocare Cardiac combines chronic care management, remote patient monitoring, cardiac diagnostics, lifestyle management, bi-directional communication, and telemedicine to help engage and manage patients better. Patients receive digital tools based on their condition(s) to help them manage their health and lifestyle following physician recommendations. Patients are given a combination of Biotricity's suite of monitoring devices which are integrated with a care plan and delivered via the Biocare Cardiac app. Physicians receive monthly reports on patient trends and customized alerts for out-of-range data, enabling them to intervene if necessary.

Click here to see a video of how physicians set up Biocare Cardiac for use with their patients.

Marcus Smith, M.D., one of the pilot project leaders at CardioVascular Health Clinic, commented, "CV Health integrated the Biocare Cardiac platform as part of our commitment to continued, ongoing care for patients. This platform technology integrates with diagnostic devices and telemedicine providing peace of mind for the patient. Importantly, it engaged patients, while providing bi-directional communication and ongoing monthly reporting that allows our practice to identify those who may need additional care, leading to better outcomes."

Dr. Hal Skinner, of Lexington Heart Specialists, spoke about the benefits for his patients after enrollment in the program, "We had patients driving hours for appointments with our doctors. The ability to enroll these patients in the Biocare Cardiac platform and monitor them with Bioheart and Biokit has changed dramatically how we manage their health. This improves their quality of life and gives everyone caring for them peace of mind. If we see something concerning a patient report, we immediately request that a patient come in for further assessment. We have already changed medications and adjusted treatment management after reviewing patients' data."

https://www.biotricity.com/biocare-cardiac/

About Biotricity

Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.

Editor's Note: A photo of Biocare Cardiac in use is available here.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor Relations:

KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
Investors@biotricity.com

Media Relations:

Erica Fiorini, Ph.D.,
Russo Partners LLC
(212) 845-4253
Erica.Fiorini@russopartnersllc.com

SOURCE: Biotricity, Inc.



View source version on accesswire.com:
https://www.accesswire.com/722323/Biotricity-Launches-Cardiac-Disease-Management-Solution-Following-2-Successful-Pilots-with-Oklahoma-Kentucky-Clinics